EA
JUNO

Emerald Acquisition’s Juno Therapeutics, Inc. JUNO Stock Holding History

Emerald Acquisition’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.11M Sell
37,023
-239
-0.6% -$7.43K ﹤0.01% 2071
2016
Q2 		$1.43M Buy
+37,262
New +$1.55M ﹤0.01% 1984

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Emerald Acquisition's JUNO Position: Q3 2016 in Review

Emerald Acquisition reduced its Juno Therapeutics, Inc. (JUNO) stake by 0.64% in Q3 2016, selling an estimated $7.43K and leaving 37,023 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Emerald Acquisition first reported a position in JUNO in Q2 2016 and has held it in 2 quarters since. The position peaked at $1.43M in Q2 2016. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

  • Emerald Acquisition held 37,023 shares of Juno Therapeutics, Inc. worth $1.11M as of Q3 2016.
  • Emerald Acquisition sold 239 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $7.43K.
  • Juno Therapeutics, Inc. made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2071 holding.
  • Emerald Acquisition first reported a position in Juno Therapeutics, Inc. in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Juno Therapeutics, Inc. position peaked at $1.43M in Q2 2016.
  • 169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.